Lupin enters into a licensing agreement with Axantia for Pegfilgrastim
Published on: Monday 31 January 2022
Under the said agreement, Axantia will register, distribute and market biosimilar Pegfilgrastim Drug products in certain GCC Countries including Jordan, Lebanon, Iraq, Sudan, Algeria, and Libya ...
